z-logo
Premium
Non‐hodgkin's lymphoma, poorly differentiated lymphocytic and mixed cell types. Results of sequential staging procedures, response to therapy, and survival of 100 patients
Author(s) -
Bitran Jacob D.,
Golomb Harvey M.,
Ultmann John E.,
Sweet Donald L.,
Lester Eric P.,
Stein Richard S.,
Miller J. Bruce,
Moran Edgar M.,
Kinnealey Ann E.,
Vardiman James E.,
Kinzie Jeannie,
Roth Nina O.
Publication year - 1978
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197807)42:1<88::aid-cncr2820420115>3.0.co;2-u
Subject(s) - medicine , copp , vincristine , prednisone , procarbazine , radiation therapy , chlorambucil , cyclophosphamide , lymphoma , chemotherapy , surgery , working formulation , gastroenterology , non hodgkin's lymphoma , heme , biochemistry , chemistry , heme oxygenase , enzyme
The results of sequential staging procedures including laparotomy, radiotherapy, and combination chemotherapy are reported for 100 patients with poorly differentiated lymphocytic (PDL) and mixed cell (MC) non‐Hodgkin's lymphoma (NHL). Twelve patients were found to have localized disease, pathologic stage (PS) I or II; 88 patients had PS III or IV disease. Bone marrow biopsy showed a high incidence of involvement and advanced 34% of the patients from CS I, II, and III to PS IV. Staging laparotomy has a very limited role in the evaluation of these patients. All of 12 patients with PS I and II NHL were treated with radiotherapy; at 5 years, they had 100% survival, 80% being disease‐free. Fifteen patients with PS III disease were treated with total nodal radiotherapy (TNRT) alone and had a median disease‐free survival of 41 months. The remaining patients with PS III and IV disease were treated with chemotherapy consisting of vincristine and prednisone (V & P); cyclophosphamide, vincristine (Oncovin®), procarbazine, and prednisorte (COPP); cyclophosphamide, vincristine (Oncovin®), adriamycin, and prednisone (COPA); or “palliative therapy”, consisting of chlorambucil and prednisone. Two‐year and 4‐year survivals for patients with diffuse lymphoma were 93% and 60%, respectively; for patients with +2 nodular lymphoma, 80% and 30%; for patients with nodular lymphomas, 76–93% and 50%, respectively. Treatment with COPP showed no advantage over V and P, “palliative therapy,” or TNRT for patients with +2 nodular and nodular disease. The likelihood of cure appears most promising for patients in complete remission (CR) with diffuse lymphoma; patients in CR with nodular lymphoma show a high rate of relapse over 5 years of observation. We conclude that staging laparotomy in PDL and MC NHL is of limited value, and that the role of aggressive chemotherapy for patients with +2 nodular and nodular lymphoma needs to be redefined.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here